Human LATS2/KPM ORF/cDNA clone-Adenovirus plasmid (NM_014572)

Cat. No.: pGMAP-SPh-160
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human LATS2/KPM adenoviral expression plasmid for LATS2 adenovirus packaging, LATS2 adenovirus.

Our GM-Adenovirus vector is optimized with the GMVC-modified Adeasy adenovirus packaging system. Find more about the GMVC-modified adenovirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to LATS2/KPM products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMAP-SPh-160
Gene Name LATS2
Accession Number NM_014572
Gene ID 26524
Species Human
Product Type Adenovirus plasmid (overexpression)
Insert Length 3267 bp
Gene Alias KPM
Fluorescent Reporter EGFP
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter EF1
Resistance Amplicin
ORF Nucleotide Sequence ATGAGGCCAAAGACTTTTCCTGCCACGACTTATTCTGGAAATAGCCGGCAGCGACTGCAAGAGATTCGTGAGGGGTTAAAACAGCCATCCAAGTCTTCGGTTCAGGGGCTACCCGCAGGACCAAACAGTGACACTTCCCTGGATGCCAAAGTCCTGGGGAGCAAAGATGCCACCAGGCAGCAGCAGCAGATGAGAGCCACCCCAAAGTTCGGACCTTATCAGAAAGCCTTGAGGGAAATCAGATATTCCTTGTTGCCTTTTGCTAATGAATCGGGCACCTCTGCAGCTGCAGAAGTGAACCGGCAAATGCTGCAGGAACTGGTGAACGCAGGATGCGACCAGGAGATGGCTGGCCGAGCTCTCAAGCAGACTGGCAGCAGGAGCATCGAGGCCGCCCTGGAGTACATCAGCAAGATGGGCTACCTGGACCCGAGGAATGAGCAGATTGTGCGGGTCATTAAGCAGACCTCCCCAGGAAAGGGGCTCATGCCAACCCCAGTGACGCGGAGGCCCAGCTTCGAAGGAACCGGCGATTCGTTTGCGTCCTACCACCAGCTGAGCGGTACCCCCTACGAGGGCCCAAGCTTCGGCGCTGACGGCCCCACGGCGCTGGAGGAGATGCCGCGGCCGTACGTGGACTACCTTTTCCCCGGAGTCGGCCCCCACGGGCCCGGCCACCAGCACCAGCACCCACCCAAGGGCTACGGTGCCAGCGTAGAGGCAGCAGGGGCACACTTCCCGCTGCAGGGCGCGCACTACGGGCGGCCGCACCTGCTGGTGCCTGGGGAACCCCTGGGCTACGGAGTGCAGCGCAGCCCCTCCTTCCAGAGCAAGACGCCGCCGGAGACCGGGGGTTACGCCAGCCTGCCCACGAAGGGCCAGGGAGGACCGCCAGGCGCCGGCCTCGCTTTCCCACCCCCTGCCGCCGGGCTCTACGTGCCGCACCCACACCACAAGCAGGCCGGTCCCGCGGCCCACCAGCTGCATGTGCTGGGCTCCCGCAGCCAGGTGTTCGCCAGCGACAGCCCCCCGCAGAGCCTGCTCACTCCCTCGCGGAACAGCCTCAACGTGGACCTGTATGAATTGGGCAGCACCTCCGTCCAGCAGTGGCCGGCTGCCACCCTGGCCCGCCGGGACTCCCTGCAGAAGCCGGGCCTGGAGGCGCCGCCGCGCGCGCACGTGGCCTTCCGGCCTGACTGCCCAGTGCCCAGCAGGACCAACTCCTTCAACAGCCACCAGCCGCGGCCCGGTCCGCCTGGCAAGGCCGAGCCCTCCCTGCCCGCCCCCAACACCGTGACGGCTGTCACGGCCGCGCACATCTTGCACCCGGTGAAGAGCGTGCGTGTGCTGAGGCCGGAGCCGCAGACGGCTGTGGGGCCCTCGCACCCCGCCTGGGTGCCCGCGCCTGCCCCGGCCCCCGCCCCCGCCCCCGCCCCGGCTGCGGAGGGCTTGGACGCCAAGGAGGAGCATGCCCTGGCGCTGGGCGGCGCAGGCGCCTTCCCGCTGGACGTGGAGTACGGAGGCCCAGACCGGAGGTGCCCGCCTCCGCCCTACCCGAAGCACCTGCTGCTGCGCAGCAAGTCGGAGCAGTACGACCTGGACAGCCTGTGCGCAGGCATGGAGCAGAGCCTCCGTGCGGGCCCCAACGAGCCCGAGGGCGGCGACAAGAGCCGCAAAAGCGCCAAGGGGGACAAAGGCGGAAAGGATAAAAAGCAGATTCAGACCTCTCCCGTTCCCGTCCGCAAAAACAGCAGAGACGAAGAGAAGAGAGAGTCACGCATCAAGAGCTACTCGCCATACGCCTTTAAGTTCTTCATGGAGCAGCACGTGGAGAATGTCATCAAAACCTACCAGCAGAAGGTTAACCGGAGGCTGCAGCTGGAGCAAGAAATGGCCAAAGCTGGACTCTGTGAAGCTGAGCAGGAGCAGATGCGGAAGATCCTCTACCAGAAAGAGTCTAATTACAACAGGTTAAAGAGGGCCAAGATGGACAAGTCTATGTTTGTCAAGATCAAAACCCTGGGGATCGGTGCCTTTGGAGAAGTGTGCCTTGCTTGTAAGGTGGACACTCACGCCCTGTACGCCATGAAGACCCTAAGGAAAAAGGATGTCCTGAACCGGAATCAGGTGGCCCACGTCAAGGCCGAGAGGGACATCCTGGCCGAGGCAGACAATGAGTGGGTGGTCAAACTCTACTACTCCTTCCAAGACAAAGACAGCCTGTACTTTGTGATGGACTACATCCCTGGTGGGGACATGATGAGCCTGCTGATCCGGATGGAGGTCTTCCCTGAGCACCTGGCCCGGTTCTACATCGCAGAGCTGACTTTGGCCATTGAGAGTGTCCACAAGATGGGCTTCATCCACCGAGACATCAAGCCTGATAACATTTTGATAGATCTGGATGGTCACATTAAACTCACAGATTTCGGCCTCTGCACTGGGTTCAGGTGGACTCACAATTCCAAATATTACCAGAAAGGGAGCCATGTCAGACAGGACAGCATGGAGCCCAGCGACCTCTGGGATGATGTGTCTAACTGTCGGTGTGGGGACAGGCTGAAGACCCTAGAGCAGAGGGCGCGGAAGCAGCACCAGAGGTGCCTGGCACATTCACTGGTGGGGACTCCAAACTACATCGCACCCGAGGTGCTCCTCCGCAAAGGGTACACTCAACTCTGTGACTGGTGGAGTGTTGGAGTGATTCTCTTCGAGATGCTGGTGGGGCAGCCGCCCTTTTTGGCACCTACTCCCACAGAAACCCAGCTGAAGGTGATCAACTGGGAGAACACGCTCCACATTCCAGCCCAGGTGAAGCTGAGCCCTGAGGCCAGGGACCTCATCACCAAGCTGTGCTGCTCCGCAGACCACCGCCTGGGGCGGAATGGGGCCGATGACCTGAAGGCCCACCCCTTCTTCAGCGCCATTGACTTCTCCAGTGACATCCGGAAGCAGCCAGCCCCCTACGTTCCCACCATCAGCCACCCCATGGACACCTCGAATTTCGACCCCGTAGATGAAGAAAGCCCTTGGAACGATGCCAGCGAAGGTAGCACCAAGGCCTGGGACACACTCACCTCGCCCAATAACAAGCATCCTGAGCACGCATTTTACGAATTCACCTTCCGAAGGTTCTTTGATGACAATGGCTACCCCTTTCGATGCCCAAAGCCTTCAGGAGCAGAAGCTTCACAGGCTGAGAGCTCAGATTTAGAAAGCTCTGATCTGGTGGATCAGACTGAAGGCTGCCAGCCTGTGTACGTGTAG
ORF Protein Sequence MRPKTFPATTYSGNSRQRLQEIREGLKQPSKSSVQGLPAGPNSDTSLDAKVLGSKDATRQQQQMRATPKFGPYQKALREIRYSLLPFANESGTSAAAEVNRQMLQELVNAGCDQEMAGRALKQTGSRSIEAALEYISKMGYLDPRNEQIVRVIKQTSPGKGLMPTPVTRRPSFEGTGDSFASYHQLSGTPYEGPSFGADGPTALEEMPRPYVDYLFPGVGPHGPGHQHQHPPKGYGASVEAAGAHFPLQGAHYGRPHLLVPGEPLGYGVQRSPSFQSKTPPETGGYASLPTKGQGGPPGAGLAFPPPAAGLYVPHPHHKQAGPAAHQLHVLGSRSQVFASDSPPQSLLTPSRNSLNVDLYELGSTSVQQWPAATLARRDSLQKPGLEAPPRAHVAFRPDCPVPSRTNSFNSHQPRPGPPGKAEPSLPAPNTVTAVTAAHILHPVKSVRVLRPEPQTAVGPSHPAWVPAPAPAPAPAPAPAAEGLDAKEEHALALGGAGAFPLDVEYGGPDRRCPPPPYPKHLLLRSKSEQYDLDSLCAGMEQSLRAGPNEPEGGDKSRKSAKGDKGGKDKKQIQTSPVPVRKNSRDEEKRESRIKSYSPYAFKFFMEQHVENVIKTYQQKVNRRLQLEQEMAKAGLCEAEQEQMRKILYQKESNYNRLKRAKMDKSMFVKIKTLGIGAFGEVCLACKVDTHALYAMKTLRKKDVLNRNQVAHVKAERDILAEADNEWVVKLYYSFQDKDSLYFVMDYIPGGDMMSLLIRMEVFPEHLARFYIAELTLAIESVHKMGFIHRDIKPDNILIDLDGHIKLTDFGLCTGFRWTHNSKYYQKGSHVRQDSMEPSDLWDDVSNCRCGDRLKTLEQRARKQHQRCLAHSLVGTPNYIAPEVLLRKGYTQLCDWWSVGVILFEMLVGQPPFLAPTPTETQLKVINWENTLHIPAQVKLSPEARDLITKLCCSADHRLGRNGADDLKAHPFFSAIDFSSDIRKQPAPYVPTISHPMDTSNFDPVDEESPWNDASEGSTKAWDTLTSPNNKHPEHAFYEFTFRRFFDDNGYPFRCPKPSGAEASQAESSDLESSDLVDQTEGCQPVYV

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-T18390-Ab Anti-LATS2 monoclonal antibody
    Target Antigen GM-Tg-g-T18390-Ag LATS2 protein
    ORF Viral Vector pGMAD000587 Human LATS2 Adenovirus plasmid
    ORF Viral Vector pGMLP-SPh-020 Human LATS2 Lentivirus plasmid
    ORF Viral Vector pGMAP-SPh-160 Human LATS2 Adenovirus plasmid
    ORF Viral Vector vGMAD000587 Human LATS2 Adenovirus particle
    ORF Viral Vector vGMLP-SPh-020 Human LATS2 Lentivirus particle
    ORF Viral Vector vGMAP-SPh-160 Human LATS2 Adenovirus particle


    Target information

    Target ID GM-T18390
    Target Name LATS2
    Gene Group Identifier
    （Target Gene ID in Homo species)         		26524
    Gene ID 100050150 (Equus caballus), 101093824 (Felis catus), 26524 (Homo sapiens), 305922 (Rattus norvegicus)
    477343 (Canis lupus familiaris), 50523 (Mus musculus), 508208 (Bos taurus), 699957 (Macaca mulatta)
    Gene Symbols & Synonyms LATS2,Lats2,KPM,4932411G09Rik
    Target Alternative Names 4932411G09Rik,KPM,Kinase phosphorylated during mitosis protein,LATS2,Large tumor suppressor homolog 2,Lats2,Serine/threonine-protein kinase LATS2,Serine/threonine-protein kinase kpm,Warts-like kinase
    Uniprot Accession Q7TSJ6,Q9NRM7
    Additional SwissProt Accessions: Q9NRM7,Q7TSJ6
    Uniprot Entry Name
    Protein Sub-location Introcelluar Protein
    Category Therapeutics Target
    Disease cancer
    Disease from KEGG Hippo signaling pathway
    Gene Ensembl ENSECAG00000009862, ENSG00000150457, ENSCAFG00845021300, ENSMUSG00000021959,ENSMUSG00000114942, ENSBTAG00000014406, ENSMMUG00000019006
    Target Classification Kinase, Tumor-associated antigen (TAA)


    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.